Is ImmunityBio, Inc. (IBRX) a Buy, Sell, or Hold?
NASDAQ : IBRX
ImmunityBio, Inc. — Institutional Ownership
$7.1 USD
-$0.3 (-4.05%)
- Volume
- 8.5M
- Average Volume
- 12.89M
- Market Capitalization
- $7.44B
- P/E Ratio
- -8.32
- Dividend Yield
- 0.00%
- Price Target
- $12.00
- Year High
- $12.43
- Year Low
- $1.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.67
Institutional Ownership Summary
Institutional Ownership %
0.46%
Investors Holding
95
change: -323 | last: 418
Increased Positions
37
change: -254 | last: 291
Reduced Positions
21
change: -38 | last: 59
New Positions
14
change: -138 | last: 152
Sold Positions
315
change: 281 | last: 34
Total Calls
2300
Total Puts
-
Put-Call Ratio
0.00
change: -80.2414 | last: 0.8024
Total Invested
41.22M
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-02-25 | NantWorks, LLC | 98.54M | 9.60% |
| 2026-02-25 | Nant Capital, LLC | 339.47M | 30.30% |
| 2026-02-25 | Cambridge Equities, LP | 261.71M | 25.50% |
| 2026-02-25 | California Capital Equity, LLC | 106.51M | 10.40% |
| 2026-02-25 | Patrick Soon-Shiong | 745.58M | 66.30% |
| 2026-02-25 | MP 13 Ventures, LLC | 261.71M | 25.50% |
| 2025-11-10 | Patrick Soon-Shiong | 743.97M | 68.90% |
| 2025-11-10 | NantMobile, LLC | 47.56M | 4.80% |
| 2025-11-10 | Cambridge Equities, LP | 261.71M | 26.60% |
| 2025-11-10 | MP 13 Ventures, LLC | 261.71M | 26.60% |
| 2025-11-10 | NantWorks, LLC | 98.54M | 10.00% |
| 2025-11-10 | Nant Capital, LLC | 339.46M | 31.50% |
| 2025-11-10 | California Capital Equity, LLC | 106.51M | 10.80% |
| 2018-02-13 | dividing (a) the total number of shares of the Issuer’s common stock being reported in this Statemen | 4.69M | 12.00% |
| 2017-02-13 | Sorrento Therapeutics, Inc. | - | 0.00% |
| 2016-02-17 | 2 | 5.62M | 6.92% |
| 2016-02-12 | 2. | 4.49M | 5.50% |
| 2016-02-12 | 2. | 4.49M | 5.50% |
IBRX Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2025-12-31 | $1.98 | 919.86M | $1.82B | $88.33M | $878.12M | $2.61B |
| 2024-12-31 | $2.56 | 697.31M | $1.79B | $143.43M | $504.17M | $2.15B |
| 2023-12-31 | $5.02 | 508.64M | $2.55B | $265.45M | $726.72M | $3.01B |
| 2022-12-31 | $5.07 | 399.9M | $2.03B | $104.64M | $723.77M | $2.65B |
| 2021-12-31 | $6.08 | 389.23M | $2.37B | $181.1M | $645.66M | $2.83B |
| 2020-12-31 | $13.33 | 383.18M | $5.11B | $34.92M | $275.55M | $5.35B |
| 2019-12-31 | $3.79 | 383.18M | $1.45B | $15.51M | $14.85M | $1.45B |
| 2018-12-31 | $1.16 | 325.05M | $377.05M | $16.82M | $6.91M | $367.14M |
| 2017-12-31 | $4.49 | 316.15M | $1.42B | $23.87M | $7.27M | $1.4B |
| 2016-12-31 | $5.72 | 328.55M | $1.88B | $8.08M | $8.21M | $1.88B |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $7.67 | 1.03B | $7.88B | $205.19M | $1.12B | $8.8B |
| 2025-12-31 | $1.98 | 989.68M | $1.96B | $88.33M | $878.12M | $2.75B |
| 2025-09-30 | $2.46 | 946.6M | $2.33B | $60.24M | $542.25M | $2.81B |
| 2025-06-30 | $2.64 | 888.22M | $2.34B | $137.66M | $535.32M | $2.74B |
| 2025-03-31 | $3.01 | 853.16M | $2.57B | $60.66M | $526.27M | $3.03B |
| 2024-12-31 | $2.56 | 733.2M | $1.88B | $143.43M | $504.17M | $2.24B |
| 2024-09-30 | $3.72 | 695.9M | $2.59B | $111.97M | $742.91M | $3.22B |
| 2024-06-30 | $6.27 | 686.94M | $4.31B | $130.1M | $735.59M | $4.91B |
| 2024-03-31 | $5.32 | 672.83M | $3.58B | $133.04M | $731.37M | $4.18B |
| 2023-12-31 | $5.02 | 590.73M | $2.97B | $265.45M | $726.72M | $3.43B |
| 2023-09-30 | $1.69 | 498.38M | $842.25M | $177.96M | $717.27M | $1.38B |
| 2023-06-30 | $2.78 | 437.46M | $1.22B | $43.51M | $819.16M | $1.99B |